公开(公告)号：US20240269231A1

公开(公告)日：2024-08-15

申请号：US18616600

申请日：2024-03-26

申请人： Ohio University

发明人： John J. Kopchick ,  Vishwajeet Puri ,  Vishva Sharma ,  Reetobrata Basu

IPC分类号： A61K38/17 ,  A61P31/00 ,  A61P35/00

CPC分类号： A61K38/1761 ,  A61P31/00 ,  A61P35/00

摘要： FSP27 compositions and methods for treating cancers are described.

公开(公告)号：US11986405B2

公开(公告)日：2024-05-21

申请号：US17847583

申请日：2022-06-23

申请人： Nfinium Vascular Technologies, LLC

发明人： Richard Eustis Fulton ,  German Todorov

IPC分类号： A61F2/86 ,  A61F2/07 ,  A61F2/95 ,  A61K38/17 ,  A61K38/18 ,  A61B8/12 ,  A61F2/06 ,  A61F2/82

CPC分类号： A61F2/86 ,  A61F2/07 ,  A61F2/95 ,  A61K38/1761 ,  A61K38/18 ,  A61B8/12 ,  A61F2002/068 ,  A61F2002/077 ,  A61F2002/823 ,  A61F2002/9511 ,  A61F2220/0008 ,  A61F2250/0067

摘要： Devices and methods are described for delivering aneurysm stabilizing substances that may act in more than one pathway to the aneurysmal wall to prevent further enlargement of an aneurysm while allowing blood flow through the treatment area. Methods, devices and features for removal of the delivery device after the treatment are also disclosed.

公开(公告)号：US20230181466A1

公开(公告)日：2023-06-15

申请号：US17759768

申请日：2021-01-29

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： Oskar Staufer ,  Yilia Plazman ,  Joachim P. Spatz

IPC分类号： A61K9/127 ,  C12N15/88 ,  C12N15/113 ,  C07K14/705 ,  A61P17/02 ,  A61K38/45 ,  A61K38/17

CPC分类号： A61K9/1272 ,  C12N15/88 ,  A61K9/1277 ,  C12N15/113 ,  C07K14/70596 ,  C07K14/70503 ,  A61P17/02 ,  A61K38/45 ,  A61K38/1709 ,  A61K38/1761 ,  C07K14/70575 ,  C12Y204/02012 ,  C12N2310/141

摘要： The present invention relates to a method for producing synthetic extracellular vesicles comprising a lipid bilayer including at least two lipids, one or more extracellular vesicle associated proteins, and optionally one or more nucleic acid molecules. The inventive synthetic extracellular vesicles are formed by emulsification using a mechanic emulsifier in the form of polymer shell stabilized synthetic extracellular vesicles. The inventive method allows producing synthetic extracellular vesicles miming the composition and function of natural extracellular vesicles. Therefore, synthetic extracellular vesicles with specific protein and nucleic acids compositions are also disclosed herein, as well as their therapeutic uses.

公开(公告)号：US11648293B2

公开(公告)日：2023-05-16

申请号：US16866600

申请日：2020-05-05

申请人： Biokine Therapeutics Ltd. ,  BioLineRx Ltd.

发明人： Amnon Peled ,  Yaron Pereg

IPC分类号： A61K39/00 ,  C07K16/28 ,  A61K38/17 ,  A61K38/04 ,  A61K47/64 ,  A61P35/00 ,  A61K38/10 ,  A61K39/12 ,  A61K39/395 ,  C07K16/30

CPC分类号： A61K38/1761 ,  A61K38/04 ,  A61K38/10 ,  A61K38/395 ,  A61K39/12 ,  A61K39/3955 ,  A61K47/646 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/30 ,  A61K2039/55522 ,  C07K2317/76 ,  A61K38/04 ,  A61K2300/00

摘要： Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.

公开(公告)号：US20180042994A1

公开(公告)日：2018-02-15

申请号：US15525618

申请日：2015-11-17

申请人： Yeda Research and Development Co. Ltd.

发明人： Atan GROSS ,  Yehudit ZALTSMAN ,  Liat PINKAS ,  Maria MARYANOVICH ,  Liat BUZAGLO ,  Antonella RUGGIERO ,  Amir BAHAT ,  Andres GOLDMAN ,  Michael MULLOKANDOV

IPC分类号： A61K38/17 ,  C12N5/00

CPC分类号： A61K38/1761 ,  C12N5/0018

摘要： Uses of agent which downregulate an activity or expression of a component participating in the mitochondrial apoptotic pathway are disclosed.

公开(公告)号：US20160271212A9

公开(公告)日：2016-09-22

申请号：US14851622

申请日：2015-09-11

申请人： UAB Research Foundation

发明人： Gattadahalli M. Anantharamaiah ,  C. Roger White ,  Himanshu Gupta

IPC分类号： A61K38/17

CPC分类号： A61K38/1709 ,  A61K38/00 ,  A61K38/1761 ,  C07K14/775 ,  C07K2319/74

摘要： The present invention provides methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides. Also disclosed are provides methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides to reduce plasma glucose levels. Methods of using the disclosed apolipoprotein E (ApoE)-mimicking peptides to treat diabetes and diabetic complications are also disclosed.

公开(公告)号：US09427460B2

公开(公告)日：2016-08-30

申请号：US14429856

申请日：2013-09-23

申请人： Ohio State Innovation Foundation

发明人： Carlo M. Croce ,  Giulia Romano

IPC分类号： C07H21/02 ,  C07H21/04 ,  C12N15/85 ,  A61K38/19 ,  A61K38/17 ,  C12Q1/68 ,  C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  A61K31/7105 ,  G01N33/574 ,  G01N33/68

CPC分类号： C12N15/1135 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/1761 ,  A61K38/19 ,  A61K45/06 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/16 ,  C12Q2600/178 ,  G01N33/574 ,  G01N33/6863 ,  G01N2800/52 ,  A61K2300/00

摘要： Methods and compositions for inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof, comprising administering an effective amount of an anti-miR-494 nucleic acid construct sufficient to target one or more tumor suppressor genes (TSGs) are described. Activation of the ERK1/2 pathway is a major determinant of diverse cellular processes and cancer development and is responsible for the transcription of several important miRNAs. Described herein is a link between the ERK1/2 pathway and BIM expression through miR-494. This ERK1/2 pathway regulates apoptosis and cell proliferation through miR-494 and mechanisms responsible for TRAIL resistance. Materials and methods related to the study and treatment of cancer are described.

摘要翻译： 描述了在有需要的受试者中体外和体内抑制致瘤性的方法和组合物，包括给予有效量的足以靶向一种或多种肿瘤抑制基因（TSG）的抗miR-494核酸构建体。 ERK1 / 2途径的激活是多种细胞过程和癌症发展的主要决定因素，并且是几种重要miRNA的转录的主要因素。 本文描述了通过miR-494的ERK1 / 2途径和BIM表达之间的联系。 这种ERK1 / 2途径通过miR-494和负责TRAIL抗性的机制调节细胞凋亡和细胞增殖。 描述了与癌症研究和治疗相关的材料和方法。

公开(公告)号：US20160215035A1

公开(公告)日：2016-07-28

申请号：US15024785

申请日：2014-09-24

申请人： MEDICENNA BIOPHARMA INC.

发明人： Fahar Merchant

IPC分类号： C07K14/54 ,  C07K14/47

CPC分类号： C07K14/5406 ,  A61K38/00 ,  A61K38/1761 ,  A61K38/193 ,  A61K38/2026 ,  C07K14/4747 ,  C07K2319/00 ,  C12N5/0602 ,  C12N5/0636 ,  C12N15/63 ,  C12N2501/48

摘要： The present invention relates to interleukin-4 receptor binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 receptor binding protein moiety joined to a pro-apoptotic Bcl-2 family member protein moiety.

摘要翻译： 本发明涉及白细胞介素-4受体结合融合蛋白。 更具体地，本发明部分地提供融合蛋白，其包括与促凋亡Bcl-2家族成员蛋白部分连接的白细胞介素-4受体结合蛋白部分。

公开(公告)号：US20160199446A1

公开(公告)日：2016-07-14

申请号：US15000988

申请日：2016-01-19

申请人： Otonomy, Inc. ,  The Regents of the University of California

发明人： Jay Lichter ,  Andrew M. Trammel ,  Fabrice Piu ,  Qiang Ye ,  Michael Christopher Scaife ,  Benedikt Vollrath ,  Sergio G. Duron ,  Luis A. Dellamary ,  Carl Lebel ,  Jeffrey P. Harris

IPC分类号： A61K38/17 ,  A61K9/00 ,  A61K38/16 ,  A61K47/36 ,  A61K38/00 ,  C12N7/00 ,  A61K9/06

CPC分类号： A61K38/1709 ,  A61K9/0046 ,  A61K9/06 ,  A61K9/14 ,  A61K38/005 ,  A61K38/162 ,  A61K38/1761 ,  A61K47/36 ,  C12N7/00 ,  C12N2740/16322

摘要： Disclosed herein are compositions and methods for the treatment of otic disorders with anti-apoptotic agent or pro-apoptotic agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

摘要翻译： 本文公开的是通过将这些组合物和组合物直接施用于灌注或通过灌注至本发明的，通过将抗凋亡剂或促凋亡剂组合物和组合物局部施用于患有耳科疾病的个体来治疗耳部病症的组合物和方法， 目标耳结构。

公开(公告)号：US20150125430A1

公开(公告)日：2015-05-07

申请号：US14534394

申请日：2014-11-06

申请人： Hadasit Medical Research Services and Development Ltd.

发明人： Dina BEN YEHUDA ,  Ihab Abd-Elrahman ,  Riki Perlman ,  Marjorie Pick

IPC分类号： A61K38/17 ,  A61K45/06 ,  A61K35/14 ,  C12N5/078 ,  C12N5/0789

CPC分类号： A61K38/1761 ,  A61K35/28 ,  A61K35/545 ,  A61K45/06 ,  C12N5/0644 ,  C12N5/0647 ,  C12N2501/48 ,  C12N2501/727 ,  C12N2501/999

摘要： Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.

摘要翻译： 提供诱导血小板生成和/或治疗受试者血小板减少症的方法。 因此，提供了一种方法，其包括使干细胞与由Livin衍生的血小板或造血祖细胞的分化潜能接触，从而诱导血小板生成。 还提供了一种方法，其包括使具有分化潜力的细胞与血小板与tLivin接触，从而诱导血小板生成。 还提供了用于在受试者中诱导血小板生成和/或治疗血小板减少症的组合物和分离的细胞群。